This is the first study to demonstrate that HIPK1 contributes to pathological cardiac hypertrophy, and that downregulating HIPK1 is beneficial to attenuate pathological hypertrophy, cardiac remodeling, and heart failure. This evidence concerns the gene HIPK1 and heart failure.